chemieunternehmen.com

Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-indivumed-announce-second-joint-drug-discovery-programme-5903

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-announces-product-development-and-manufacturing-agreement-with-oncoresponse-5899

Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-initiates-construction-of-first-jpodr-facility-in-north-america-5895

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-enters-into-multi-year-collaboration-with-msd-around-facility-of-the-future-5897

Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/bayer-and-evotec-form-new-strategic-alliance-focusing-on-polycystic-ovary-syndrome-5893

Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-expand-ipsc-collaboration-5891

Evotec SE today announced successful achievement of a third milestone in their diabetes research alliance with Sanofi, resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-third-milestone-in-cell-therapy-diabetes-alliance-with-sanofi-5885

Evotec SE today announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Under the terms of the new agreement, Sanofi will transfer its liquid compounds to Evotec in Toulouse over the next 2 years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-service-agreement-with-sanofi-to-create-a-centralised-global-sample-management-hub-in-toulouse-5881

Evotec spin-off Topas Therapeutics GmbH (“Topas”), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris („PV“), an orphan autoimmune disease.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-spin-off-topas-therapeutics-announces-start-of-phase-1-trial-with-tpm203-in-pemphigus-vulgaris-5883